Robin S. Turpin
Research Subjects
Robin S. Turpin has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Claire E. Sharda
Integrated Health Management, Merck & Co., Inc., Whitehouse Station, New Jersey
2 shared publicationsJeffrey B. Simmons
Merck Managed Care, Merck & Co., Inc., Roswell, Georgia
2 shared publicationsAlan D. Tice
John A. Burns School of Medicine, University of Hawaii, Honolulu, USA
1 shared publication- Benjamin A. Lipsky
Department of Medicine, University of Washington, Seattle, WA 98195, USA
1 shared publication Brian Haggert
Merck Managed Care Marketing Programs, Merck & Co., Inc., West Point, Pennsylvania
1 shared publicationCatherine M. Baase
1 shared publication
Latest Publications
- 1 December 2007
- Published by SAGE Publications in Disease Management
- Vol. 10 (6) , 305-310
Patient Adherence: Present State and Future Directions
- 1 December 2007
- Published by SAGE Publications in Disease Management
- Vol. 10 (6) , 305-310
Patient Adherence: Present State and Future Directions
- Open Access
- 15 May 2007
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 64 (10) , 1080-1086
Comparative costs of ertapenem and piperacillin–tazobactam in the treatment of diabetic foot infections
Purpose. To evaluate potential cost savings, trial data were used to determine the clinical outcomes for i.v. ertapenem given once daily and i.v. piperacillin–tazobactam given every six hours daily in treating diabetic foot infections. Methods. A cost-minimization analysis (CMA) was conducted on the drug-dosing data of the subset of patients enrolled in a recent double-blind randomized trial who were treated solely as inpatients and were clinically evaluable at fi nal assessment (n = 99). Cost per dose was calculated from (a) average hospital acquisition price per dose for ertapenem ($40.52) or piperacillin–tazobactam ($13.58), (b) average U.S. wages and benefi ts for labor, based on nine published time-and-motion studies of i.v. antibiotic preparation and administration ($3.10), and (c) consumable supplies, using a 40% discount off the manufacturer list price ($2.90). For each patient, the actual number of antibiotic doses given was multiplied by total cost per dose. Results. There were no significant differences between antibiotic groups with respect to patient demographics, percentage with a severe wound, and mean days of i.v. therapy. Compared with piperacillin–tazobactam, patients treated with ertapenem received significantly fewer mean doses (25.5 versus 7.5; p < 0.0001) and lower antibiotic-related costs ($502.76 versus $355.55, respectively; p < 0.001). The $147.21 difference between groups accounts for approximately 3% of total hospital Medicare reimbursements for these infections. Conclusion. A CMA of treatment of diabetic foot infections showed that, compared with piperacillin–tazobactam given four times daily i.v., ertapenem given once daily i.v. was associated with lower drug acquisition and supply costs and less time and labor devoted to preparation and administration of i.v. therapy.
- 15 May 2007
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 64 (10) , 1080-1086
Open AccessComparative costs of ertapenem and piperacillin–tazobactam in the treatment of diabetic foot infections
Purpose. To evaluate potential cost savings, trial data were used to determine the clinical outcomes for i.v. ertapenem given once daily and i.v. piperacillin–tazobactam given every six hours daily in treating diabetic foot infections. Methods. A cost-minimization analysis (CMA) was conducted on the drug-dosing data of the subset of patients enrolled in a recent double-blind randomized trial who were treated solely as inpatients and were clinically evaluable at fi nal assessment (n = 99). Cost per dose was calculated from (a) average hospital acquisition price per dose for ertapenem ($40.52) or piperacillin–tazobactam ($13.58), (b) average U.S. wages and benefi ts for labor, based on nine published time-and-motion studies of i.v. antibiotic preparation and administration ($3.10), and (c) consumable supplies, using a 40% discount off the manufacturer list price ($2.90). For each patient, the actual number of antibiotic doses given was multiplied by total cost per dose. Results. There were no significant differences between antibiotic groups with respect to patient demographics, percentage with a severe wound, and mean days of i.v. therapy. Compared with piperacillin–tazobactam, patients treated with ertapenem received significantly fewer mean doses (25.5 versus 7.5; p < 0.0001) and lower antibiotic-related costs ($502.76 versus $355.55, respectively; p < 0.001). The $147.21 difference between groups accounts for approximately 3% of total hospital Medicare reimbursements for these infections. Conclusion. A CMA of treatment of diabetic foot infections showed that, compared with piperacillin–tazobactam given four times daily i.v., ertapenem given once daily i.v. was associated with lower drug acquisition and supply costs and less time and labor devoted to preparation and administration of i.v. therapy.
- 1 November 2004
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 46 (11) , 1123-1133
Reliability and Validity of the Stanford Presenteeism Scale
This study reports the reliability and validity of the 13-item Stanford Presenteeism Scale (SPS). The SPS differs from similar scales by focusing on knowledge-based and production-based workers. Data were obtained from administrative and medical claims databases and from a survey that incorporated the SPS, SF-36, and the Work Limitations Questionnaire. Sixty-three percent (7797) of employees responded. Cronbach's alpha (0.83) indicates adequate reliability. Factor analysis identified two underlying factors, “completing work” and “avoiding distraction.” Knowledge-based workers load on “completing work” (α = 0.97), whereas production-based workers load on “avoiding distraction” (α = 0.98). There were significant and positive relationships between the SPS, SF-36, and Work Limitations Questionnaire. The SPS demonstrates a high degree of reliability and validity and may be ideal for employers who seek a single scale to measure health-related productivity in a diverse employee population.
- 1 November 2004
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 46 (11) , 1123-1133
Reliability and Validity of the Stanford Presenteeism Scale
This study reports the reliability and validity of the 13-item Stanford Presenteeism Scale (SPS). The SPS differs from similar scales by focusing on knowledge-based and production-based workers. Data were obtained from administrative and medical claims databases and from a survey that incorporated the SPS, SF-36, and the Work Limitations Questionnaire. Sixty-three percent (7797) of employees responded. Cronbach's alpha (0.83) indicates adequate reliability. Factor analysis identified two underlying factors, “completing work” and “avoiding distraction.” Knowledge-based workers load on “completing work” (α = 0.97), whereas production-based workers load on “avoiding distraction” (α = 0.98). There were significant and positive relationships between the SPS, SF-36, and Work Limitations Questionnaire. The SPS demonstrates a high degree of reliability and validity and may be ideal for employers who seek a single scale to measure health-related productivity in a diverse employee population.
- 1 January 2004
- Published by Springer Nature in Disease Management and Health Outcomes
- Vol. 12 (6) , 377-383
Improving Treatment Regimen Adherence in Coronary Heart Disease by Targeting Patient Types
- 1 January 2004
- Published by Springer Nature in Disease Management and Health Outcomes
- Vol. 12 (6) , 377-383
Improving Treatment Regimen Adherence in Coronary Heart Disease by Targeting Patient Types
- 1 March 2003
- Published by SAGE Publications in Disease Management
- Vol. 6 (1) , 43-51
The HEDIS® Performance NAVIGATOR for Controlling High Blood Pressure: A Resource to Assist Health Plans Improve Patient Adherence
This article describes how the resources in the Health Plan Employer and Data Information Set (HEDIS®; a registered trademark of the National Committee for Quality Assurance) Performance NAVIGATOR for Controlling High Blood Pressure (HEDIS NAVIGATOR) developed by Merck & Co., Inc. assist managed care organizations in understanding and encouraging the active involvement of their members in adhering to a treatment plan developed in partnership by physicians and patients. (HEDIS is a set of standardized performance measures that enable purchasers and consumers to make informed decisions regarding the quality of managed care organizations.) The discussion uses the Health Belief and Transtheoretical Models as a framework to better understand patient behavior change. Targeted strategies to facilitate adherence are also addressed. Examples of structured programs using nationally recommended guidelines and HEDIS NAVIGATOR resources are included to illustrate coordinated efforts to assist patients with high blood pressure adhere to their treatment plan and help managed care organizations improve patient outcomes and HEDIS scores.
- 1 March 2003
- Published by SAGE Publications in Disease Management
- Vol. 6 (1) , 43-51
The HEDIS® Performance NAVIGATOR for Controlling High Blood Pressure: A Resource to Assist Health Plans Improve Patient Adherence
This article describes how the resources in the Health Plan Employer and Data Information Set (HEDIS®; a registered trademark of the National Committee for Quality Assurance) Performance NAVIGATOR for Controlling High Blood Pressure (HEDIS NAVIGATOR) developed by Merck & Co., Inc. assist managed care organizations in understanding and encouraging the active involvement of their members in adhering to a treatment plan developed in partnership by physicians and patients. (HEDIS is a set of standardized performance measures that enable purchasers and consumers to make informed decisions regarding the quality of managed care organizations.) The discussion uses the Health Belief and Transtheoretical Models as a framework to better understand patient behavior change. Targeted strategies to facilitate adherence are also addressed. Examples of structured programs using nationally recommended guidelines and HEDIS NAVIGATOR resources are included to illustrate coordinated efforts to assist patients with high blood pressure adhere to their treatment plan and help managed care organizations improve patient outcomes and HEDIS scores.